recent advances in peptide linkers for antibody drug conjugates Antibody - Antibody-drug conjugate review drug conjugates Recent Advances in Peptide Linkers for Antibody-Drug Conjugates

Antibody-drug conjugate review The field of antibody-drug conjugates (ADCs) has seen remarkable progress, largely driven by innovations in linker technology. Peptide linkers, in particular, play a crucial role in connecting the potent cytotoxic drug to the targeting antibody, ensuring precise delivery to cancer cells while minimizing systemic toxicityThe results showed that the improved ADC demonstrated enhanced antitumor efficacy and outperformed conventionalADCs. In vitro experiments also showed that this .... Recent advances in peptide linkers for antibody-drug conjugates are focusing on enhancing stability, selectivity, and the controlled release of the drug at the tumor site, thereby improving therapeutic efficacy and patient outcomes.

The Evolving Landscape of Peptide Linkers

Peptide linkers are designed to be stable in circulation but cleavable within the tumor microenvironment or inside cancer cells. This targeted release mechanism is fundamental to the success of ADCs. Historically, linkers were broadly categorized as either cleavable or non-cleavable. However, the ongoing research into peptide linkers is expanding this classification, exploring new cleavage mechanisms and optimizing linker properties to overcome existing limitations.

Key areas of advancement include:

* Enhanced Stability and Selectivity: Developing peptide sequences that resist premature cleavage in the bloodstream is paramount. Recent work has focused on identifying specific peptide motifs that are efficiently recognized and cleaved by enzymes or under conditions prevalent in the tumor microenvironment, such as low pH or specific protease activity.Recent Advances in Peptide Linkers of Antibody-Drug ... This selective cleavage ensures that the drug is released primarily at the target site, reducing off-target effects.Recent Advances in Peptide LinkersofAntibody–Drug Conjugatespubs.acs.org.

* Novel Cleavage Strategies: Beyond traditional lysosomal or cathepsin-cleavable linkers, researchers are exploring dual-cascade triggering mechanisms and other sophisticated strategiesCraig Lindsley, Ph.D., FRSC, FASPET, FAAS, FNAI's Post. For instance, novel double SI linker strategies have been developed, demonstrating enhanced therapeutic potential by offering a more controlled and efficient drug release profile. These advanced systems can respond to multiple stimuli, further refining the selectivity of drug release.

* Improved Drug Conjugation: Advances in conjugation methodologies, including site-specific conjugation, are also impacting linker design. Creating homogeneous ADCs with a defined drug-to-antibody ratio (DAR) through improved linker-antibody attachment and linker-payload attachment is a significant area of focus. This precision in conjugation contributes to more predictable pharmacokinetics and improved efficacy and toxicity profilesAntibody-drug conjugates: recent advances in ... - Springer Link.

Innovations in Peptide Sequences and Mimics

The core of a peptide linker is its amino acid sequence. Significant research efforts are dedicated to designing novel peptide sequences or peptidomimetics that offer improved cleavage kinetics and stability.The review discussesrecent advancements in linker chemistry for antibody-drug conjugates(ADCs), which are transforming cancer therapy. For example, linkers that are specifically cleaved by enzymes like cathepsins, which are often overexpressed in tumors, are a subject of intense study.2024年6月6日—Over the past few years, numerous new linkers have been developed, includingcathepsin-cleavable linkers, acid-cleavable linkers, GSH-cleavable ... Furthermore, the exploration of exolinker strategies and the development of linkers that respond to specific intracellular conditions are pushing the boundaries of ADC design.作者：K Tsuchikama·2018·被引用次数：884—The development of site-specific conjugation methodologies for constructing homogeneousADCsis an especially promising path to improving ADC design, which will ...

The optimization of linker properties is critical for improving drug selectivity and reducing off-target effects. This includes fine-tuning the linker's hydrophilicity/hydrophobicity, charge, and overall structure to ensure optimal interaction with both the antibody and the payload, as well as efficient cellular uptake and processing作者：S Balamkundu·2023·被引用次数：81—This review reportsrecent advances in the design and structure–activity relationship studiesof various peptide/peptidomimetic linkers in this field..

Future Directions and Therapeutic Potential

The continuous evolution of peptide linker technology is paving the way for next-generation ADCs with superior efficacy and safety profiles.2026年1月30日—As of December 2025, 21ADCshave received global approval (Table 1). An analysis of these therapeutics reveals a dominance of cleavablelinkers... As linker chemistry advances, it enables the conjugation of increasingly potent cytotoxic payloads and the development of ADCs that can overcome drug resistance mechanisms. The insights gained from structure-activity relationship studies of various peptide linkers are invaluable for guiding future design efforts.

The development of ADCs is an ongoing journey, and peptide linkers remain a cornerstone of this therapeutic modality.Recent Advances in ADCs By focusing on sophisticated design principles, novel cleavage mechanisms, and precise conjugation strategies, researchers are unlocking new possibilities for targeted cancer therapy, promising enhanced outcomes for patients.